Vasopharm Announces Enrolment of First Patient in Phase III Traumatic Brain Injury (TBI) Trial

Home/News/News/Vasopharm Announces Enrolment of First Patient in Phase III Traumatic Brain Injury (TBI) Trial

Vasopharm Announces Enrolment of First Patient in Phase III Traumatic Brain Injury (TBI) Trial

Vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced that the first patient has been enrolled in to the NOSTRA III (NOSynthase in TRAumatic Brain Injury) trial – a phase III clinical trial assessing efficacy and safety of Ronopterin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain (TBI) injury patients.


Original source of this content: http://www.prnewswire.com/news-releases/vasopharm-announces-enrolment-of-first-patient-in-phase-iii-traumatic-brain-injury-tbi-trial-592404911.html